Scholars Central

Review articlePublished 27 Feb 2019

Thalidomide a An Overview and the Species-Specific Teratogenicity

Authors: Sidra Shafique

Research Journal of Congenital Diseases

Volume 2 · Issue 1 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Thalidomide (TD) is the drug in clinical use since over half a century for variable indications such as Leprosy. In 1960s, the use of TD lead to birth of about 10,000 babies with phocomelia. Later on, TD was removed from the market. In spite of Thalidomide Embryopathy (TE), this drug has recently been approved for the treatment of multiple myeloma for specific indications. Species resistance to develop limb deformities was the main reason of its unrecognized teratogenicity during preclinical toxicity testing. The purpose of this review is to discuss the brief history of this drug and the current discovery of a possible mechanism of species- specificity of TE involving SALL4 degradation by Thalidomide-Cereblon (TD-CRBN) complex.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Research Journal of Congenital Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalResearch Journal of Congenital Diseases
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Sidra Shafique”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels